Skip to Content

Efficacy of Osimertinib in resected EGFR-Mutated stage IB-IIIA NSCLC

In this MEDtalk, the ADAURA study is presented by Masahiro Tsuboi, a Thoracic surgeon in Japan. The study explores osimertinib as adjuvant therapy for patients with resected EGFR-mutated non-small-cell lung cancer and indicates osimertinib to be an effective adjuvant treatment for these patients.

Masahiro Tsuboi

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top